$CRVO News

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

CervoMed Files Prospectus Related To Offer And Resale Of 10.08M Shares Of Common Stock By Selling Stockholders

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed Agreed To Raise $10M in Direct Stock Offering Of 2.5M Shares At $4/Share, Plans to Use Stock Sale Proceeds for Working Capital

CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally

Top Midday Gainers

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)

CervoMed Announces $10M Registered Direct Offering Of 2.5M Shares At $4/Share To Fund Working Capital And General Corporate Purposes

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies

CORRECTION: Reported June 15, 2026: CervoMed Form4 Filing Shows Director Joshua S. Boger Acquired ~2.87M Share-Equivalent Position Via $3.14/Unit Private Placement (955,414 Shares Plus Matching Series B and C Warrants); Holds 20% Position As Of June 11, 2026

CervoMed Insiders Lose Out As Stock Sinks To US$2.45